LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nonradioactive Serotonin Release Assay Compared to Gold Standard

By LabMedica International staff writers
Posted on 01 Feb 2016
Print article
The JANUS Automated Liquid Handling Workstation
The JANUS Automated Liquid Handling Workstation (Photo courtesy of Perkin Elmer)
The serotonin release assay (SRA) is considered the gold standard laboratory test for heparin-induced thrombocytopenia (HIT) and the classical SRA method uses platelets loaded with radiolabeled serotonin to evaluate platelet activation by HIT immune complexes.

Laboratory tests for HIT consist of immunoassays, usually enzyme-linked immunosorbent assays (ELISAs), and functional platelet activation assays. Immunoassays detect the presence of immunoglobulins that bind heparin: PF4 complexes, while functional tests detect platelet activation by immune complexes consisting of macromolecular aggregates of heparin: PF4 and antibody.

Scientists at the ARUP Laboratories Institute (Salt Lake City, UT, USA) and their colleagues have validated the performance characteristics of a high-performance liquid chromatography (HPLC) SRA method. The team used serum samples stored frozen until the time of evaluation that had been submitted to their laboratory for HIT testing. Reagent platelets were obtained by collecting blood from healthy donors known to be reactive and with no history of HIT, platelet dysfunction, or current nonsteroidal anti-inflammatory drugs (NSAID) use.

Assay setup was automated on a JANUS liquid handling system (PerkinElmer, Waltham, MA, USA), although platelets were pipetted manually. Serotonin released from reagent platelets was quantitated (ng/mL) by HPLC on a gel permeation chromatography (GPC), size exclusion chromatography (SEC), 1260 instrument (Agilent Technologies; Santa Clara, CA, USA) with fluorescent detection (excitation 285 nm, emission 345 nm). Results were expressed as percentage release and classified as positive, negative, or indeterminate based on previously published cutoffs.

The serum samples from 250 subjects with suspected HIT were tested in the HPLC-SRA and with the radioactive method. Concordant classifications were observed in 230 samples (92%). Sera from 41 healthy individuals tested negative. Between-run imprecision studies showed standard deviation of less than 6% release for positive, weak positive and negative serum pools. Stability studies demonstrated stability after two freeze–thaw cycles or up to a week of refrigeration.

The authors concluded that the HPLC-SRA has robust performance characteristics, equivalent to the classic radioactive method, which has long been considered the gold standard assay for HIT. Results from nonradioactive SRA methods using novel serotonin detection methods provide equivalent information to radioactive methods for HIT diagnostic algorithms but avoid the laboratory complexities of working with radioactivity. The HPLC-SRA method has been optimized to accommodate the demands placed on our high-volume reference laboratory by use of an automated dilutor to perform many pipetting steps and laboratory-developed software to perform calculations. The study was published in the February 2016 issue of the International Journal of Laboratory Hematology.

Related Links:

ARUP Laboratories Institute 
Perkin Elmer 
Agilent Technologies 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.